Advanced Cancers Associated With Mesothelin Expression

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Advanced Cancers Associated With Mesothelin Expression trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06756035

CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibo…

United States70 participantsStarted 2025-03-31

Treatment: CT-95

All recent trials (2 shown)

CompletedPhase 1

NCT03872206

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin…

United States95 participantsStarted 2019-04-16

Treatment: HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target